Itolizumab, a novel anti-CD6 monoclonal antibody : a safe and efficacious biologic agent for management of psoriasis
INTRODUCTION: Psoriasis, a chronic immune-mediated skin disorder is associated with significant physical, psychological, and quality of life impairments. Along with well-documented genetic and environmental factors, immunological factors also contribute to the pathogenesis of psoriasis. Among the immunological factors, CD6 - dependent T-cell proliferation to form Th1 and Th17 cells play a major role in the pathogenesis of psoriasis. Itolizumab is the first humanized IgG1 monoclonal antibody, which selectively targets CD6. Areas covered: The current article presents the pharmacology of itolizumab and provides a review of the currently available data on the efficacy and safety of itolizumab for management of moderate to severe plaque psoriasis. Expert opinion: The use of biologics to attenuate the immune-mediated pathological events in psoriasis is a relatively well-established clinical practice. However, the safety and efficacy of biologics continues to be an unsettled topic of ongoing research. While available data seems to suggest that itolizumab may be a safer option, additional studies with higher sample sizes and active comparators are needed before definitive conclusions can be drawn on the place of itolizumab in the management of psoriasis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Expert opinion on biological therapy - 17(2017), 3 vom: 01. März, Seite 395-402 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dogra, Sunil [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.07.2017 Date Revised 02.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14712598.2017.1279601 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM267787030 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM267787030 | ||
| 003 | DE-627 | ||
| 005 | 20231224221428.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14712598.2017.1279601 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0892.xml |
| 035 | |a (DE-627)NLM267787030 | ||
| 035 | |a (NLM)28064543 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dogra, Sunil |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Itolizumab, a novel anti-CD6 monoclonal antibody |b a safe and efficacious biologic agent for management of psoriasis |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.07.2017 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Psoriasis, a chronic immune-mediated skin disorder is associated with significant physical, psychological, and quality of life impairments. Along with well-documented genetic and environmental factors, immunological factors also contribute to the pathogenesis of psoriasis. Among the immunological factors, CD6 - dependent T-cell proliferation to form Th1 and Th17 cells play a major role in the pathogenesis of psoriasis. Itolizumab is the first humanized IgG1 monoclonal antibody, which selectively targets CD6. Areas covered: The current article presents the pharmacology of itolizumab and provides a review of the currently available data on the efficacy and safety of itolizumab for management of moderate to severe plaque psoriasis. Expert opinion: The use of biologics to attenuate the immune-mediated pathological events in psoriasis is a relatively well-established clinical practice. However, the safety and efficacy of biologics continues to be an unsettled topic of ongoing research. While available data seems to suggest that itolizumab may be a safer option, additional studies with higher sample sizes and active comparators are needed before definitive conclusions can be drawn on the place of itolizumab in the management of psoriasis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Anti-CD6 | |
| 650 | 4 | |a Itolizumab | |
| 650 | 4 | |a monoclonal antibody | |
| 650 | 4 | |a plaque psoriasis | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antigens, CD |2 NLM | |
| 650 | 7 | |a Antigens, Differentiation, T-Lymphocyte |2 NLM | |
| 650 | 7 | |a CD6 antigen |2 NLM | |
| 650 | 7 | |a itolizumab |2 NLM | |
| 650 | 7 | |a XQQ2RHV14N |2 NLM | |
| 700 | 1 | |a Uprety, Shraddha |e verfasserin |4 aut | |
| 700 | 1 | |a Suresh, Swaroop Hassan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on biological therapy |d 2001 |g 17(2017), 3 vom: 01. März, Seite 395-402 |w (DE-627)NLM116190124 |x 1744-7682 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2017 |g number:3 |g day:01 |g month:03 |g pages:395-402 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14712598.2017.1279601 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2017 |e 3 |b 01 |c 03 |h 395-402 | ||